Semaglutide Dosage Chart: Genetics & Clinical Guidance

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide weight loss dosages typically escalate from 0.25 mg weekly to a maximum of 2.4 mg, with most efficacy studies reporting meaningful weight reduction at 1.7 mg and 2.4 mg doses. Understanding this dosage progression helps patients set realistic expectations and recognize when provider adjustments align with clinical evidence.

Beyond the standard dosing schedule, individual response varies significantly based on metabolic factors, gastrointestinal tolerance, and underlying genetic predispositions in GLP-1 receptor pathways. PlexusDx emphasizes precision-guided treatment planning—combining dosage best practices with biomarker and genetic context to support more personalized conversations with your healthcare provider.

Standard Semaglutide Dosage Progression for Weight Loss

The FDA-approved semaglutide weight loss regimen (Wegovy) follows a 16-week titration protocol: weeks 1–4 start at 0.25 mg, weeks 5–8 increase to 0.5 mg, weeks 9–12 advance to 1.0 mg, and weeks 13–16 reach 1.7 mg maintenance. Clinical trials demonstrated approximately 5% weight loss at 1.7 mg and 10–15% at 2.4 mg doses.

Compounded semaglutide follows similar pharmacokinetic principles but may offer flexible dosing schedules based on provider assessment and individual tolerance. The goal is reaching a therapeutic dose where efficacy balances with gastrointestinal side effects—not necessarily maximal dose for every patient.

Dosage Tolerance Factors: Genetic Predispositions and Biomarker Insights

How quickly patients tolerate semaglutide escalation depends on GI sensitivity, liver function, and genetic variation in GLP-1 receptor signaling. The GLP1R rs6923761 variant, measured in PlexusDx's Precision Peptide Genetic Test, may influence receptor responsiveness and gastrointestinal tolerance at higher doses.

Dosage Stage	Common Tolerance Response	Genetic/Biomarker Context	Provider Consideration
0.25–0.5 mg (Weeks 1–8)	Usually well-tolerated; mild nausea in 20–30% of patients	GLP1R variants may predict early satiety or mild GI effects	Baseline assessment of appetite and nausea tolerance
1.0–1.7 mg (Weeks 9–16)	Gastrointestinal effects peak; appetite suppression evident	Individuals with specific GLP1R alleles may experience stronger or milder responses	Monitor for persistent nausea, vomiting, or constipation
2.0–2.4 mg (Maintenance/Higher)	Peak efficacy but increased GI side effect risk	FTO rs9939609 and MC4R rs17782313 variants relate to baseline metabolic regulation	Assess whether dose escalation justifies side effect burden for individual patient
Below-standard or Paused Dosing	Patient tolerates lower doses better; slower weight loss trajectory	Some patients achieve meaningful results at 1.0–1.7 mg due to genetic sensitivity	Personalized approach may optimize efficacy-to-tolerability ratio

Biomarker Monitoring During Semaglutide Dose Escalation

As semaglutide doses increase, liver enzymes, kidney function, and pancreatic markers warrant monitoring—especially in patients with pre-existing metabolic conditions. Baseline biomarkers establish a safety reference; regular checks during escalation help providers detect early signs of drug-related stress or intolerance.

Genetic predispositions in metabolic pathways (FTO, MC4R variants) may correlate with baseline metabolic inflammation or insulin resistance. Understanding these predispositions can inform whether biomarker changes during therapy reflect treatment efficacy or early warning signals requiring dose adjustment.

Who Benefits from Modified or Standard Dosing: Safety and Eligibility

Standard semaglutide escalation suits patients with stable liver and kidney function, no history of medullary thyroid cancer, and adequate tolerance for incremental GI side effects. Patients with severe gastroparesis, chronic pancreatitis, or recent gastrointestinal surgery may benefit from slower titration or lower maintenance doses under provider supervision.

Genetic screening via Precision Peptide Genetic Test may identify individuals with high predisposition for strong GLP-1 pathway activity, suggesting potential for lower efficacious doses or heightened monitoring for adverse effects. Always discuss genetic test results with a qualified healthcare provider before adjusting your dosage plan.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in four key peptide pathway variants—GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—that may help provide context for individual semaglutide response patterns. These predispositions relate to baseline receptor sensitivity, metabolic inflammation, and appetite regulation, supporting a more informed dosage conversation with your provider.

The genetic test does not predict exact medication response or guarantee a specific weight loss outcome; instead, it identifies predispositions in genetic pathways relevant to GLP-1 therapy. When interpreted alongside clinical biomarkers and your medical history, these insights can support provider decision-making around optimal dosing strategy and expected tolerability.

PlexusDx compounded semaglutide ($149/mo) combines genetic and biomarker context with licensed 503A pharmacy preparation, enabling personalized dosing discussions. Standalone genetic testing ($298) or as an add-on ($99) allows you to approach dosage optimization with evidence-informed precision rather than trial-and-error adjustment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the standard starting dose of semaglutide for weight loss?

The standard starting dose is 0.25 mg injected subcutaneously once weekly for weeks 1–4. Doses increase gradually every 4 weeks: 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13+), and optionally 2.4 mg. Always follow your provider's specific dosing schedule.

How much weight loss should I expect at each dosage level?

Clinical trial data shows approximately 5% body weight reduction at 1.7 mg and 10–15% at 2.4 mg over 68 weeks. Individual results vary based on diet, exercise, genetics, and baseline metabolism. Your provider can set realistic expectations for your specific situation.

Does PlexusDx offer compounded semaglutide with flexible dosing options?

Yes. PlexusDx provides compounded semaglutide from licensed 503A pharmacies at $149/mo. Your provider can work with our pharmacies to establish a dosing plan tailored to your tolerance and clinical goals, distinct from standardized brand schedules.

What genetic factors influence how I tolerate semaglutide dosage escalation?

Variants in GLP1R (rs6923761), FTO (rs9939609), and MC4R (rs17782313) relate to receptor sensitivity, metabolic regulation, and appetite signaling. PlexusDx's Precision Peptide Genetic Test identifies these predispositions; discuss results with your provider to refine your dosing strategy and side effect expectations.

Can I stay on a lower semaglutide dose if I tolerate it well and see results?

Yes. While clinical trials often escalate to 2.4 mg, many patients achieve meaningful weight loss and good tolerability at 1.0–1.7 mg doses. Work with your provider to determine whether continuing at a lower maintenance dose aligns with your personal goals and comfort level.

Semaglutide Weight Loss Dosage Chart: Biomarkers, Genetics, and Provider-Guided Adjustment